<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640535</url>
  </required_header>
  <id_info>
    <org_study_id>HM-MOLZ-301</org_study_id>
    <nct_id>NCT01640535</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients</brief_title>
  <official_title>Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the efficacy of Concomitant Montelukast
      Sodium and Levocetirizine Dihydrochloride is superior to that of Levocetirizine and
      Montelukast monotherapies and to compare the safety and tolerability of Concomitant
      Montelukast Sodium and Levocetirizine Dihydrochloride to those of Levocetirizine and
      Montelukast monotherapies in Perennial Allergic Rhinitis (PAR) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      randomized, double-blind, active-controlled, multicenter, phase 3 trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Daytime Nasal Symptom Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in Mean Daytime Nasal Symptom Score from baseline at Weeks 3-4(2 weeks) of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Nighttime Nasal Symptom from baseline at Weeks 1-2 (2 weeks) and Weeks 3-4 (2 weeks) of treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in Mean Nighttime Nasal Symptom from baseline at Weeks 1-2 (2 weeks) and Weeks 3-4 (2 weeks) of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Composite Symptom Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in Mean Composite Symptom Score from baseline at Weeks 1-2 (2 weeks) and Weeks 3-4 (2 weeks) of treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">283</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Test arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Matching placebo of Montelukast sodium 10mg + Levocetirizine dihydrochloride 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Montelukast sodium 10mg + matching placebo of Levocetirizine dihydrochloride 5mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast + Levocetirizine</intervention_name>
    <description>Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)</description>
    <arm_group_label>Test arm</arm_group_label>
    <other_name>Singulair Tablet, Xyzal Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine</intervention_name>
    <description>Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)</description>
    <arm_group_label>Comparator arm I</arm_group_label>
    <other_name>Xyzal Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)</description>
    <arm_group_label>Comparator arm II</arm_group_label>
    <other_name>Singulair Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with at least 2 years history of PAR prior to the study

          -  Positive results of skin prick test

          -  Patients who provided a signed written informed consent form

          -  Patients who are able and willing to complete subject diaries

          -  Patients who agree to maintain consistency in their surroundings throughout the study
             period

          -  At Visit, 2 patients whose symptom scores recorded in the subject diary meet all of
             the followings during the last one week of baseline period A.Daily mean of 6 points or
             above for Daytime Nasal Symptom Score (maximum 12 points) B.Daily mean of 1.8 points
             or above for Daytime Nasal Obstruction Symptom Score (maximum 3 points)

        Exclusion Criteria:

          -  Patients also with non-allergic rhinitis with different causes.

          -  Patients with severe asthma who meet the followings.

          -  Presence of nasal polyps or any clinically important nasal anomaly.

          -  History of acute â€¢ chronic sinusitis within 30 days of Visit 1

          -  History of intranasal / eye surgeries within 3 months of Visit 1

          -  Initiation of immunotherapy or dose modification within 1 month prior to Visit 1

          -  Upper respiratory infections including cold and systemic infections within 3 weeks of
             Visit 1.

          -  Chronic use of tricyclic antidepressants, beta agonists, bronchodilators, etc. that
             may affect the efficacy of study drug

          -  At Visit 2, patients who recorded Daytime Nasal Symptom Scores for fewer than 4 days
             in the subject diary during the last one week of baseline period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungmi PARK, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hanmi Pharmaceutical Company Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2012</study_first_posted>
  <last_update_submitted>April 4, 2013</last_update_submitted>
  <last_update_submitted_qc>April 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

